Preview

Urology Herald

Advanced search

The role of genetic factors in the development of recurrent urolithiasis

https://doi.org/10.21886/2308-6424-2022-10-3-54-64

Contents

Scroll to:

Abstract

Introduction. Urolithiasis is a polyethylological disease of the urinary system. Epidemiological data on urolithiasis is disappointing: over the past 30 years, the number of patients with urolithiasis has increased by 48.57%, and the mortality rate has increased by 17.12%. Single nucleotide polymorphisms in various genes can influence the risk of development and recurrence of this disease. Early diagnosis of a patient's genetic predisposition to primary or recurrent urolithiasis is important for the effective prevention of urolithiasis.

Objective. To explore the association of SNP (Single Nucleotide Polymorphism) rs3134057 (TNFRS11B), rs851982 (ESR1), rs1540339 (VDR), rs2202127 (CASR), rs526906 (KL) with the development of recurrent urolithiasis.

Materials and methods. The observed group consisted of 96 patients with a single-sided ureteral stone, of whom 45 had recurrent urolithiasis; the control group consisted of 51 volunteers. Venous blood samples were collected from all participants, DNA was extracted from the blood and analyzed for each SNP studied by real-time polymerase chain reaction. We analyze the data obtained on genotype and presence or absence of urolithiasis in the participants using a binomial logistic regression model.

Results. An association was found between the presence of SNP rs3134057 in the TNFRS11B gene (odds ratio (OR), 1.92; confidence interval (CI): 1.05-3.52; p = 0.031) and the development of recurrent urolithiasis.

Conclusion. The association of rs3134057 with urolithiasis relapse leads us to investigating the effect of this SNP on serum osteoprotegerin levels, a product of the TNFRS11B gene.

For citations:


Savilov A.V., Jain M., Anokhin D.M., Kotsepuga M.E., Tivtikyan A.S., Samokhodskaya L.M., Okhobotov D.A., Afanasyevskaya E.V., Mamedov V.N., Shurygina A.S., Shershnev S.P., Kamalov A.A. The role of genetic factors in the development of recurrent urolithiasis. Urology Herald. 2022;10(3):54-64. (In Russ.) https://doi.org/10.21886/2308-6424-2022-10-3-54-64

INTRODUCTION

The number of cases of urolithiasis in the world has increased by 48.57% over the past three decades, and worldwide mortality due to it has increased by 17.12% [1]. The prevalence of this disease on the territory of the Russian Federation over 15 years (2005–2019) in all the regions has become 16.20% higher [2].

Urolithiasis is a polyetiological disease of the urinary system, when salts are accumulated in the urinary tract [3, 4]. The pathogenesis of the disease is also based on genetic factors [5]. While studying the hereditary factor by the twin method, it was revealed that in patients with risk factors for urolithiasis, the heritability of the development of clinical disease forms was 45.00 – 50.00% [6]. In particular, single nucleotide polymorphism (SNP) in various genes may affect the risk of development and recurrence of this disease [7]. Early detection of genetic predisposition to this disease manifestation and recurrence may be the most important link in urolithiasis prevention [8]. Thus, the study of the role of polymorphisms in urolithiasis pathogenesis is an urgent task.

In this work, SNPs in TNFRS11B (Tumor necrosis factor receptor superfamily member 11B, or osteoprotegerin; rs3134057), ESR1 (Estrogen receptor isoform 1; rs851982), VDR (Vitamin D receptor; rs1540339), CASR (Calcium-sensing receptor; rs2202127), KL (Klotho protein; rs526906), whose protein products are somehow involved in maintaining calcium homeostasis or in the development of nephrological pathologies, were selected. Thus, TNFR-mediated (Tumor necrosis factor receptor) signaling is necessary for the adhesion of calcium oxalate crystals to the luminal membrane of the renal tubules, which is the main initiating mechanism of oxalate nephropathy [9], and the therapeutic TNFR blockade inhibits the development of progressive forms of nephrocalcinosis in this disease [10]. In postmenopausal women taking estrogen hormone replacement therapy, urine pH increases and calcium phosphate content is reduced compared to those who do not take estrogen drugs after menopause [11], which confirms the role of estrogen receptors in calcium homeostasis. The protein product of the VDR gene naturally regulates the biological activity of vitamin D, an important regulator of the calcium balance in the body. Thus, patients receiving excessive doses of vitamin D are more likely to suffer from urolithiasis [12]. The physiological effects caused by CASR are extensive, among them slowing the reabsorption of calcium ions in the nephron, increasing the excretion of water, citrate, protons, and reabsorption of phosphate ions. According to the literature, the presence of polymorphisms that reduce the CASR density on cells is associated with more frequent development of nephrolithiasis [13]. The KL forms a negative feedback loop with the mechanism of calcitriol synthesis, the most biologically active form of vitamin D. Mice deficient in this protein were characterized by an increased concentration of calcium in blood plasma [12]. In addition, KL can directly interact with non-selective TRPV5 (Transient receptor potential cation channel subfamily V member 5) cation channels involved in transcellular calcium reabsorption by distal nephron tubules [12].

The study aimed to explore the SNP associations (rs3134057, rs851982, rs1540339, rs2202127, rs526906) with the development of recurrent urolithiasis.

MATERIALS AND METHODS

Study design. The study was approved by the Ethics Committee of the Medical Scientific and Educational Center, Lomonosov Moscow State University (Protocol No. 12/20 dated December 21, 2020) and conducted in accordance with the postulates of the Declaration of Helsinki. All participating patients provided signed forms of voluntary informed consent. In total, 96 people were included in the study between January 2021 and January 2022; among them, 45 patients suffered from urolithiasis recurrence, and from the localization of the main concretion in one of the ureters (the main group); the control group consisted of 51 volunteers who did not suffer from urolithiasis, whose family history was also not burdened by this disease. The clinical and demographic characteristics of the study participants are presented in Table 1. The stone size was assessed using computed tomography of the urinary system organs without contrast enhancement.

Biomaterial sampling and studying. Venous blood samples were taken in a volume of 4.5 ml in vacuum tubes («Greiner Bio-One GmbH», Kremsmünster, Austria, 2016). Intact blood was aliquoted in 1.5 ml tubes and stored at -20 °C. After defrosting, each blood sample was thoroughly mixed by pulse vortexing. DNA was isolated from 200 µl of intact blood using QIAamp DNA Blood Mini Kit reagents («Qiagen GmbH», Hilden, Germany, 2006) using the QIAcube robotic system («Qiagen GmbH», Hilden, Germany, 2016) according to the manufacturer's recommendations.

Genotyping. The analysis of SNPs in the studied genes of patients of the main and control groups was carried out by means of using real-time PCR on a Real-time CFX96 Touch amplifier («Bio-Rad Laboratories, Inc.», Hercules, CA, USA, 2018) with the following thermal cycling conditions: exposure at 95 °C for 10 minutes, 40 cycles of denaturation at 92 °C for 15 seconds, and annealing/elongation at 60 °C for 1 minute. Information on the SNPs studied and the reagents used for their detection is presented in Table 2.

Statistical analysis. The analysis was carried out using the software SNPStats («Institut Català d'Oncologia», Barcelona, Spain, 2006) and IBM SPSS Statistics 22.0 («IBM Corp.», New York, NY, USA, 2013). Binomial logistic regression served as a statistical model for data analysis. A statistically significant difference was p < 0.05.

Table 1. Clinical and demographic characteristics of study participants

Features

Observation group

(n = 45)

Control group

(n = 51)

Age [M ± SD]

57.82 ± 16.05

50.94 ± 15.454

Sex [n (%)]

Male

33 (73.33)

38 (74.51)

Female

12 (26.67)

13 (25.49)

First stone size, mm [M ± SD]

7.39 ± 3.54

Second stone size (if applicable), mm [M ± SD]

4.55 ± 2.20

Third stone size (if applicable), mm [M ± SD]

3.75 ± 1.55

Hounsfield density, Hounsfield units [M ± SD]

824.94 ± 391.13

Comorbidities [n (%)]:

Coronary heart disease

9 (20.00)

12 (23.53)

Hypertension (any stage)

I

5 (11.11)

3 (5.88)

II

5 (11.11)

III

1 (2.22)

Diabetes type 2

2 (4.44)

14 (27.45)

Other pathologies of the cardiovascular system

1 (2.22)

Other general metabolic abnormalities

2 (4.44)

Other pathologies associated with neoplasms

3 (6.67)

Table 2. Information about the studied SNPs and the reagents used to detect them

Geneа

SNP а

Substitution а

Localization а

Frequency of the minor allele in the population а

Reagent cat. number ThermoFisher b

TNFRSF11B

rs3134057

A > G

Intron

0.39

C__27463975_10

ESR1

rs851982

T > C

Intron

0.38

C___2496816_10

VDR

rs1540339

C > T

Intron

0.36

C___8716064_1_

CASR

rs2202127

G > A

Intron

0.33

C__16159347_10

KL

rs526906

A > G

Intron

0.17

C____592765_10

Note. SNP — single-nucleotide polymorphism; TNFRSF11B — TNF Receptor Superfamily Member 11b; ESR1 — Estrogen Receptor 1; VDR — vitamin D receptor; CASR — Calcium-sensing receptor; KL — klotho

a — data were obtained from dbSNP database [14]

b — the above reagents are validated off-the-shelf products manufactured by Thermo Fisher Scientific («Thermo Fisher Scientific Inc.», Waltham, MA, USA)

RESULTS

As a result of statistical analysis, an association was found between the presence of SNP rs3134057 in the TNFRS11B gene (odds ratio (OR) – 1.92; confidence interval (CI): 1.05–3.52; p = 0.031) and the development of recurrent urolithiasis, while no such statistically significant association was found for the other studied SNPs in the ESR1, CASR, VDR, and KL genes (rs851982, rs2202127, rs1540339, rs526906, respectively) (p > 0.05) (Table 3, Fig.).

To find an association of combinations of the SNPs mentioned above with the development of recurrent urolithiasis, an analysis of the non-equilibrium coupling of alleles was performed, which showed the absence of a statistically significant interaction between the SNPs studied (p > 0.05). A sub-analysis of haplotype combinations for 2 – 5 SNPs also did not reveal statistically significant combinations (p > 0.05).

Table 3. Results of a statistical analysis of the relationship between the presence of SNPs and the development of recurrent urolithiasis

Gene

SNP

OR (95% CI)

p

TNFRSF11B

rs3134057

1.92 (1.05)

0.03

ESR1

rs851982

1.42 (0.79)

0.24

VDR

rs1540339

0.94 (0.53)

0.82

CASR

rs2202127

0.88 (0.50)

0.67

KL

rs526906

1.51 (0.73)

0.26

Note. SNP — single nucleotide polymorphism; OR — odds ratio; CI — confidence interval; TNFRSF11B — TNF Receptor Superfamily Member 11b; ESR1 — Estrogen Receptor 1; VDR — vitamin D receptor; CASR — Calcium-sensing receptor; KL — klotho

Figure. Distribution of genotypes among the control and observation groups

DISCUSSION

All the SNPs studied are intronic. According to the Haploview service [15], the studied polymorphisms are located in regions with pronounced nonequilibrium coupling of alleles of their corresponding genes and can be associated with the degree of expression of the latter.

For some of the studied SNPs, their direct effects on metabolism and physiological processes in cell lines and multicellular organisms are known. Therefore, the introduction of the rs851982 ESR1 minor allele leads to an increase in the activity of the promoter of the ESR1 and RMND1 genes (required for the Meiotic Nuclear Division protein 1) in the cell lines ER+ MCF-7, BT-474 and ER+MCF-7, BT-474, ER−Bre-80, respectively (Estrogen receptor “+” Michigan Cancer Foundation-7; Breast tumor 474; Estrogen receptor “–“ breast-80); chromatin immunoprecipitation showed that the gene with rs8519882 SNP was enriched with GATA3 (GATA binding protein 3), but the GATA3 planting density did not differ between cells with SNP and normal allele [16]. In addition, the presence of rs851982 SNP is statistically significantly associated with a higher mineral density of the femoral neck (p = 0.012) [17]. Despite these data, the authors found no connection between rs851982 and recurrent urolithiasis development, which is consistent with the data of domestic scientists [18].

The presence of the minor allele rs1540339 of the VDR gene (both in the heterozygous variant and in the homozygous one: OR = 0.55; 95% CI: 0.35 – 0.88; p = 0.01 and OR = 0.404; 95% CI: 0.20 – 0.78; p = 0.005, respectively) reduces susceptibility to tuberculosis. In addition, tuberculosis patients have a significantly smaller amount of VDR mRNA. Both facts may indicate the influence of rs1540339 on the expression of the VDR gene. It is important to note that VDR plays a key role in the development of the immune response to infection, triggering the assembly of the phagolysosomal complex after binding to the active form of vitamin D [19]. However, data on the role of rs1540339 in the development of urolithiasis are contradictory, as there are works both confirming [20] and refuting its role [21]. In this study, no such connection was also found, and perhaps a further study of the effect of rs1540339 on the patient's predisposition to urolithiasis is required.

Up to date, there are no data from in vivo and in vitro studies for the rs2202127 SNP in the CASR gene demonstrating a change in expression in the presence of a minor allele. At the same time, it is known that the presence of rs2202127 is associated with an increased level of serum calcium [22], which may indirectly confirm its role in calcium metabolism.

Apolikhin et al. (2016) found an association of recurrent urolithiasis with rs2202127 SNP polymorphism in the CASR gene [18]. However, in the course of subsequent studies and in the course of the present study, these data were not confirmed [20]. Therefore, the existing data on the effect of rs2202127 SNP on recurrent urolithiasis are contradictory, indicating the need for larger studies with the allocation of additional subgroups of patients.

In this and similar studies, it was not possible to detect the association of rs526906 SNP in the KL gene with the development of urolithiasis [19][22], although it was shown that the presence of polymorphism in the KL gene led to an increase in the expression of the latter [23].

Currently, there are no data from in vivo and in vitro studies on changes in the expression of the TNFRS11B gene in the presence of rs526906 SNP; however, this polymorphism was associated with a reduced mass of the distal part of the radius [24]. The authors of this paper found that the presence of TNFRS11B polymorphism was associated with the development of urolithiasis, while in the study by Apolikhin et al. (2016), the indicated association was not found [18], which may be explained by differences in the inclusion conditions: only patients with recurrent urolithiasis, as well as the localization of the ureteral stone, were included in the present study.

In addition to the SNPs investigated in this article, there are other promising polymorphisms for studying genetic predictors of the development of urolithiasis. For example, there is evidence of a statistically significant association of polymorphism of the ORAI1 (Calcium release-activated calcium modulator 1) gene (rs7135617) with the risk of calcium oxalate stones [20].  ORAI1 is a subunit of the calcium membrane channel, which is activated when calcium reserves are depleted. Chou et al. (2011) identified two SNPs of this gene, rs12313273 and rs6486795, which increase the risk of developing calcium nephrolithiasis [25].

Limitations. A limitation of this study is the small sample size of patients.

CONCLUSION

The study of genetic predictors of urolithiasis development is an important and promising scientific direction in the context of trends toward a more personalized approach in modern medicine. Knowledge of the genetic predisposition to the disease in a particular patient can allow timely preventive measures and attention to modifiable risk factors, which can later significantly improve the patient’s quality of life, as well as improve economic indicators in the health sector.

In connection with the discovery of an association between the presence of rs3134057 SNP in the TNFRS11B gene and the development of recurrent urolithiasis, an urgent task is to study the effect of this SNP on the serum level of osteoprotegerin, a product of the TNFRS11B gene.

Key moments:

  1. Osteoprotegerin plays an important role in the pathogenesis of recurrent urolithiasis; therefore, monitoring its level in various biomaterials may be of practical interest.
  2. The presence of the minor allele rs3134057 SNP in the TNFRSF11B gene is significantly associated with recurrent urolithiasis development; genotyping for this polymorphism may be applied as part of the assessment of genetic predisposition to this disease.
  3. The location of rs3134057 SNP in the intron of the TNFRS11B gene indicates its effect on the direct expression of osteoprotegerin, and not its structure. Thus, in future studies to study the level of osteoprotegerin in recurrent urolithiasis, to increase diagnostic accuracy, it is recommended to establish individual threshold values for each of the genotypes according to rs3134057

References

1. Qian X, Wan J, Xu J, Liu C, Zhong M, Zhang J, Zhang Y, Wang S. Epidemiological Trends of Urolithiasis at the Global, Regional, and National Levels: A Population-Based Study. Int J Clin Pract. 2022;30;2022:6807203. https://doi.org/10.1155/2022/6807203

2. Gadzhiev N, Prosyannikov M, Malkhasyan V, Akopyan G, Somani B, Sivkov A, Apolikhin O, Kaprin A. Urolithiasis prevalence in the Russian Federation: analysis of trends over a 15-year period. World J Urol. 2021;39(10):3939-3944. https://doi.org/10.1007/s00345-021-03729-y

3. EAU Guidelines. Edn. presented at the EAU Annual Congress Amsterdam, 2022. ISBN 978-94-92671-16-5. URL: https://uroweb.org/guidelines/urolithiasis

4. Pak CY. Kidney stones. Lancet. 1998;351(9118):1797-801. https://doi.org/10.1016/S0140-6736(98)01295-1

5. Monico CG, Milliner DS. Genetic determinants of urolithiasis. Nat Rev Nephrol. 2011;8(3):151-62. https://doi.org/10.1038/nrneph.2011.211

6. Goldfarb DS, Avery AR, Beara-Lasic L, Duncan GE, Goldberg J. A Twin Study of Genetic Influences on Nephrolithiasis in Women and Men. Kidney Int Rep. 2018;4(4):535-540. https://doi.org/10.1016/j.ekir.2018.11.017

7. Atmoko W, Raharja PAR, Birowo P, Hamid ARAH, Taher A, Rasyid N. Genetic polymorphisms as prognostic factors for recurrent kidney stones: A systematic review and meta-analysis. PLoS One. 2021;16(5):e0251235. https://doi.org/10.1371/journal.pone.0251235

8. Tivtikyan A.S., Savilov A.V., Okhobotov D.A., Tarasova A.A., Shershnev S.P., Samokhodskaya L.M., Strigunov A.A., Afanasyevskaya E.V., Nesterova O.Yu., Kamalov A.A. Hereditary factor of metaphylaxis of urolithiasis: current state of the issue. Experimental and Clinical Urology. 2022;15(1):76-84. (In Russ.) https://doi.org/10.29188/2222-8543-2022-15-1-76-84

9. Carney EF. Stones: TNFRs mediate CaOx deposition in hyperoxaluria. Nat Rev Nephrol. 2016;12(11):651. https://doi.org/10.1038/nrneph.2016.143

10. Mulay SR, Eberhard JN, Desai J, Marschner JA, Kumar SV, Weidenbusch M, Grigorescu M, Lech M, Eltrich N, Müller L, Hans W, Hrabě de Angelis M, Vielhauer V, Hoppe B, Asplin J, Burzlaff N, Herrmann M, Evan A, Anders HJ. Hyperoxaluria Requires TNF Receptors to Initiate Crystal Adhesion and Kidney Stone Disease. J Am Soc Nephrol. 2017;28(3):761-768. https://doi.org/10.1681/ASN.2016040486

11. Lieske JC, Rule AD, Krambeck AE, Williams JC, Bergstralh EJ, Mehta RA, Moyer TP. Stone composition as a function of age and sex. Clin J Am Soc Nephrol. 2014;9(12):2141-6. https://doi.org/10.2215/CJN.05660614

12. Liu W, Chen M, Li M, Ma H, Tong S, Lei Y, Qi L. Vitamin D receptor gene (VDR) polymorphisms and the urolithiasis risk: an updated meta-analysis based on 20 case-control studies. Urolithiasis. 2014;42(1):45-52. https://doi.org/10.1007/s00240-013-0619-y

13. Vezzoli G, Macrina L, Magni G, Arcidiacono T. Calcium-sensing receptor: evidence and hypothesis for its role in nephrolithiasis. Urolithiasis. 2019;47(1):23-33. https://doi.org/10.1007/s00240-018-1096-0

14. The Single Nucleotide Polymorphism database by NCBI. Accessed May 11, 2022. URL: https://ncbiinsights.ncbi.nlm.nih.gov/tag/dbsnp/

15. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005;21(2):263-5. https://doi.org/10.1093/bioinformatics/bth457

16. Dunning AM, Michailidou K, Kuchenbaecker KB, Thompson D, French JD, Beesley J, Healey CS, Kar S, Pooley KA, Lopez-Knowles E, Dicks E, Barrowdale D, Sinnott-Armstrong NA, Sallari RC, Hillman KM, Kaufmann S, Sivakumaran H, Moradi Marjaneh M, Lee JS, Hills M, Jarosz M, Drury S, Canisius S, Bolla MK, Dennis J, Wang Q, Hopper JL, Southey MC, Broeks A, Schmidt MK, Lophatananon A, Muir K, Beckmann MW, Fasching PA, Dos-Santos-Silva I, Peto J, Sawyer EJ, Tomlinson I, Burwinkel B, Marme F, Guénel P, Truong T, Bojesen SE, Flyger H, González-Neira A, Perez JI, Anton-Culver H, Eunjung L, Arndt V, Brenner H, Meindl A, Schmutzler RK, Brauch H, Hamann U, Aittomäki K, Blomqvist C, Ito H, Matsuo K, Bogdanova N, Dörk T, Lindblom A, Margolin S, Kosma VM, Mannermaa A, Tseng CC, Wu AH, Lambrechts D, Wildiers H, Chang-Claude J, Rudolph A, Peterlongo P, Radice P, Olson JE, Giles GG, Milne RL, Haiman CA, Henderson BE, Goldberg MS, Teo SH, Yip CH, Nord S, Borresen-Dale AL, Kristensen V, Long J, Zheng W, Pylkäs K, Winqvist R, Andrulis IL, Knight JA, Devilee P, Seynaeve C, Figueroa J, Sherman ME, Czene K, Darabi H, Hollestelle A, van den Ouweland AM, Humphreys K, Gao YT, Shu XO, Cox A, Cross SS, Blot W, Cai Q, Ghoussaini M, Perkins BJ, Shah M, Choi JY, Kang D, Lee SC, Hartman M, Kabisch M, Torres D, Jakubowska A, Lubinski J, Brennan P, Sangrajrang S, Ambrosone CB, Toland AE, Shen CY, Wu PE, Orr N, Swerdlow A, McGuffog L, Healey S, Lee A, Kapuscinski M, John EM, Terry MB, Daly MB, Goldgar DE, Buys SS, Janavicius R, Tihomirova L, Tung N, Dorfling CM, van Rensburg EJ, Neuhausen SL, Ejlertsen B, Hansen TV, Osorio A, Benitez J, Rando R, Weitzel JN, Bonanni B, Peissel B, Manoukian S, Papi L, Ottini L, Konstantopoulou I, Apostolou P, Garber J, Rashid MU, Frost D; EMBRACE, Izatt L, Ellis S, Godwin AK, Arnold N, Niederacher D, Rhiem K, Bogdanova-Markov N, Sagne C, Stoppa-Lyonnet D, Damiola F; GEMO Study Collaborators, Sinilnikova OM, Mazoyer S, Isaacs C, Claes KB, De Leeneer K, de la Hoya M, Caldes T, Nevanlinna H, Khan S, Mensenkamp AR; HEBON, Hooning MJ, Rookus MA, Kwong A, Olah E, Diez O, Brunet J, Pujana MA, Gronwald J, Huzarski T, Barkardottir RB, Laframboise R, Soucy P, Montagna M, Agata S, Teixeira MR; kConFab Investigators, Park SK, Lindor N, Couch FJ, Tischkowitz M, Foretova L, Vijai J, Offit K, Singer CF, Rappaport C, Phelan CM, Greene MH, Mai PL, Rennert G, Imyanitov EN, Hulick PJ, Phillips KA, Piedmonte M, Mulligan AM, Glendon G, Bojesen A, Thomassen M, Caligo MA, Yoon SY, Friedman E, Laitman Y, Borg A, von Wachenfeldt A, Ehrencrona H, Rantala J, Olopade OI, Ganz PA, Nussbaum RL, Gayther SA, Nathanson KL, Domchek SM, Arun BK, Mitchell G, Karlan BY, Lester J, Maskarinec G, Woolcott C, Scott C, Stone J, Apicella C, Tamimi R, Luben R, Khaw KT, Helland Å, Haakensen V, Dowsett M, Pharoah PD, Simard J, Hall P, García-Closas M, Vachon C, Chenevix-Trench G, Antoniou AC, Easton DF, Edwards SL. Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. Nat Genet. 2016;48(4):374-86. https://doi.org/10.1038/ng.3521

17. Guo Y, Zhang LS, Yang TL, Tian Q, Xiong DH, Pei YF, Deng HW. IL21R and PTH may underlie variation of femoral neck bone mineral density as revealed by a genome-wide association study. J Bone Miner Res. 2010;25(5):1042-8. https://doi.org/10.1359/jbmr.091040

18. Apolikhin O.I., Apolikhin O.I., Sivkov A.V., Konstantinova O.V., Slominsky P.A., Tupitsyna T.V., Kalinichenko D.N. Genetic risk factors for recurrent urolithiasis. Experimental and Clinical Urology 2016;(3):127-130. (In Russ.) eLIBRARY ID: 28870118 EDN: YHTWTN

19. de Albuquerque Borborema ME, de Souza Pereira JJ, Dos Santos Peixoto A, Crovella S, Schindler HC, da Silva Rabello MC, de Azevêdo Silva J. Differential distribution in vitamin D receptor gene variants and expression profile in Northeast Brazil influences upon active pulmonary tuberculosis. Mol Biol Rep. 2020;47(9):7317-22. https://doi.org/10.1007/s11033-020-05762-3

20. Apolihin O.I., Sivkov A.V., Konstantinova O.V., Slominskiy P.A., Tupicyna T.V., Kalinichenko D.N. The search for the polymorphic variants of the gene candidates of urolithiasis in Russian population. Experimental and Clinical Urology. 2013;(3);56-60. (In Russ.) eLIBRARY ID: 20386630 EDN: REDDJN

21. Konstantinova O.V., Apolikhin O.I., Sivkov A.V., Slominskiy P.A., Tupitsyna T.V., Kalinichenko D.N. Znachenie molekulyarno-geneticheskikh metodov pri poiske faktorov riska mnozhestvennykh kamney pochek u bol'nykh urolitiazom v rossiyskoy populyatsii. Urology reports (St. - Petersburg). 2017;7(1S):55-56. (In Russ.) URL: https://journals.eco-vector.com/uroved/article/view/6610

22. Vinayagamoorthy N, Yim SH, Jung SH, Park SW, Kim YJ, Kim BJ, Chung YJ. Association of common variants in the calcium-sensing receptor gene with serum calcium levels in East Asians. J Hum Genet. 2015;60(8):407-12. https://doi.org/10.1038/jhg.2015.46

23. Bostrom MA, Hicks PJ, Lu L, Langefeld CD, Freedman BI, Bowden DW. Association of polymorphisms in the klotho gene with severity of non-diabetic ESRD in African Americans. Nephrol Dial Transplant. 2010;25(10):3348-55. https://doi.org/10.1093/ndt/gfq214

24. Roshandel D, Holliday KL, Pye SR, Ward KA, Boonen S, Vanderschueren D, Borghs H, Huhtaniemi IT, Adams JE, Bartfai G, Casanueva FF, Finn JD, Forti G, Giwercman A, Han TS, Kula K, Lean ME, Pendleton N, Punab M, Silman AJ, Wu FC, Thomson W, ONeill TW; EMAS Study Group. Influence of polymorphisms in the RANKL/RANK/OPG signaling pathway on volumetric bone mineral density and bone geometry at the forearm in men. Calcif Tissue Int. 2011;89(6):446-55. https://doi.org/10.1007/s00223-011-9532-y

25. Chou YH, Juo SH, Chiu YC, Liu ME, Chen WC, Chang CC, Chang WP, Chang JG, Chang WC. A polymorphism of the ORAI1 gene is associated with the risk and recurrence of calcium nephrolithiasis. J Urol. 2011;185(5):1742-6. https://doi.org/10.1016/j.juro.2010.12.094


About the Authors

A. V. Savilov
Mandryk Central Military Clinical Hospital
Russian Federation

Alexander V. Savilov — M.D.; Urologist

8A Bld. Bolshaya Olenya Str., Moscow, 107076, Russian Federation



M. Jain
Lomonosov Moscow State University — Medical Research and Education Center; Lomonosov Moscow State University — Faculty of Fundamental Medicine
Russian Federation

Mark Jain — Trainee Researcher, Laboratory Diagnostics Division; Postgraduate student, Dept. of Multidisciplinary Clinical Training

27 Bld. 1 Lomonosovsky Ave., Moscow, 10119234, Russian Federation

27 Bld. 1, Lomonosovsky Ave., Moscow, 119192, Russian Federation



D. M. Anokhin
Lomonosov Moscow State University — Faculty of Fundamental Medicine
Russian Federation

Daniil M. Anokhin — Student, Faculty of Fundamental Medicine

27 Bld. 1, Lomonosovsky Ave., Moscow, 119192, Russian Federation



M. E. Kotsepuga
Lomonosov Moscow State University — Faculty of Fundamental Medicine
Russian Federation

Maria Y. Kotsepuga — Student

27 Bld. 1, Lomonosovsky Ave., Moscow, 119192, Russian Federation



A. S. Tivtikyan
Lomonosov Moscow State University — Medical Research and Education Center
Russian Federation

Alexander S. Tivtikyan — M.D., Urologist

27 Bld. 1 Lomonosovsky Ave., Moscow, 10119234, Russian Federation



L. M. Samokhodskaya
Lomonosov Moscow State University — Medical Research and Education Center; Lomonosov Moscow State University — Faculty of Fundamental Medicine
Russian Federation

Larisa M. Samokhodskaya — M.D., Сand.Sc.(Med), Assoc. Prof.(Docent); Head, Laboratory Diagnostics Division; Assoc.Prof., Dept. of Multidisciplinary Clinical Training

27 Bld. 1 Lomonosovsky Ave., Moscow, 10119234, Russian Federation

27 Bld. 1, Lomonosovsky Ave., Moscow, 119192, Russian Federation



D. A. Okhobotov
Lomonosov Moscow State University — Medical Research and Education Center; Lomonosov Moscow State University — Faculty of Fundamental Medicine
Russian Federation

Dmitry A. Okhobotov — M.D., Сand.Sc.(Med); Urologist, Medical Research and Education Center; Assoc.Prof., Dept. of Urology and Andrology, Faculty of Fundamental Medicine

27 Bld. 1 Lomonosovsky Ave., Moscow, 10119234, Russian Federation



E. V. Afanasyevskaya
Lomonosov Moscow State University — Faculty of Fundamental Medicine
Russian Federation

Elizaveta V. Afanasyevskaya — M.D.; Postgraduate student, Dept. of Urology and Andrology

27 Bld. 1, Lomonosovsky Ave., Moscow, 119192, Russian Federation



V. N. Mamedov
City Clinical Hospital No. 31— the Healthcare Department of Moscow
Russian Federation

Vadim N. Mamedov — M.D., Сand.Sc.(Med); Urologist

42 Lobachevsky St., Building 1, Moscow, 119415, Russian Federation



A. S. Shurygina
Lomonosov Moscow State University — Faculty of Fundamental Medicine
Russian Federation

Alevtina S. Shurygina — Resident, Faculty of Fundamental Medicine

27 Bld. 1, Lomonosovsky Ave., Moscow, 119192, Russian Federation



S. P. Shershnev
Mandryk Central Military Clinical Hospital
Russian Federation

Sergei P. Shershnev — M.D.; Head, Urology Division

8A Bld. Bolshaya Olenya Str., Moscow, 107076, Russian Federation



A. A. Kamalov
Mandryk Central Military Clinical Hospital; Lomonosov Moscow State University — Faculty of Fundamental Medicine
Russian Federation

Armais A. Kamalov — MD, Dr.Sc.(Med), Full Prof., Academician of RAS; Director, Medical Research and Education Center; Head, Dept. of Urology and Andrology

8A Bld. Bolshaya Olenya Str., Moscow, 107076, Russian Federation

27 Bld. 1, Lomonosovsky Ave., Moscow, 119192, Russian Federation



Review

For citations:


Savilov A.V., Jain M., Anokhin D.M., Kotsepuga M.E., Tivtikyan A.S., Samokhodskaya L.M., Okhobotov D.A., Afanasyevskaya E.V., Mamedov V.N., Shurygina A.S., Shershnev S.P., Kamalov A.A. The role of genetic factors in the development of recurrent urolithiasis. Urology Herald. 2022;10(3):54-64. (In Russ.) https://doi.org/10.21886/2308-6424-2022-10-3-54-64

Views: 1393


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2308-6424 (Online)